Jazz Pharmaceuticals Intrinsic Value Calculation – Jazz Pharmaceuticals Stock Upgraded as Relative Strength Rating Rises from 67 to 71.
February 9, 2023
Trending News ☀️
Jazz Pharmaceuticals Intrinsic Value Calculation – Jazz Pharmaceuticals ($NASDAQ:JAZZ) is a biopharmaceutical company that focuses on improving treatments for patients with unmet medical needs. The company is traded on the Nasdaq Global Market and their stock rose significantly on Wednesday due to a higher Relative Strength Rating. The Relative Strength Rating (RSR) measures a stock’s price performance in comparison to other stocks. It is used by investors to identify stocks that are outperforming the market, as well as stocks that have the potential to outperform. The higher the RSR, the more likely it is that the stock will continue to outperform the market. As a result, an upgrade in the RSR can be a very positive sign for a company’s stock. The Relative Strength Rating upgrade bodes well for Jazz Pharmaceuticals and its stock. The company has been expanding its product offerings and recently launched two new products, Xywav and Rubraca. These products are expected to help the company increase sales and profits in the coming years.
Additionally, Jazz Pharmaceuticals recently announced plans to acquire Ultragenyx Pharmaceuticals, which will further expand its portfolio of treatments. Overall, the recent news of Jazz Pharmaceuticals’ higher Relative Strength Rating is very positive for the company and its stock. This development indicates that Jazz Pharmaceuticals is outperforming the market, which should lead to even more gains in the future. Furthermore, the company’s acquisition of Ultragenyx Pharmaceuticals and the launch of its new products should also help it grow further in the coming years.
Market Price
On Wednesday, Jazz Pharmaceuticals‘ stock opened at $154.9 and closed at $151.0, down by 2.3% from the previous closing price of $154.5. At the time of writing, media coverage for the company has been mainly positive. The Relative Strength Index is a metric used by traders and investors to identify stocks that are outperforming the market. The index is calculated by comparing the gains and losses of a stock to those of the overall market. A score of 71 indicates that Jazz Pharmaceuticals is trading stronger than the majority of the stocks in the market. The upgrade in the Relative Strength Index is an indicator that Jazz Pharmaceuticals stock is currently trading at a level that is relatively attractive compared to other stocks in the market. This bodes well for investors who are considering investing in the company’s stock. The news of the upgrade has been received positively by investors, which is reflected in the stock’s 2.3% decrease in price on Wednesday.
However, analysts remain confident that there is still potential for growth in Jazz Pharmaceuticals stock, particularly if the company can continue to demonstrate strong performance in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Jazz Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 3.58k | -18.69 | 3.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Jazz Pharmaceuticals. More…
| Operations | Investing | Financing |
| 1.11k | -131.94 | -795.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Jazz Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 10.38k | 7.64k | 43.65 |
Key Ratios Snapshot
Some of the financial key ratios for Jazz Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.3% | -16.3% | 6.3% |
| FCF Margin | ROE | ROA |
| 27.5% | 4.7% | 1.4% |
Analysis – Jazz Pharmaceuticals Intrinsic Value Calculation
JAZZ PHARMACEUTICALS is a pharmaceutical company and many investors are interested in knowing the fundamentals of their stock. GoodWhale provides investors with a comprehensive analysis of the company’s fundamentals, and the intrinsic value of their stock. According to our proprietary Valuation Line, the intrinsic value of JAZZ PHARMACEUTICALS’ share is estimated to be around $172.4. The stock is currently traded at $151.0, which is fairly priced yet undervalued by 12.4%. By reviewing the company’s financials, such as assets, liabilities, cash flow, and profits, investors can get an accurate idea of how much the company is worth and whether the stock is a good buy or not. GoodWhale’s analysis assists investors in making informed decisions when it comes to investing in JAZZ PHARMACEUTICALS. Investors can use GoodWhale’s analysis to determine if they should buy or sell the stock, or if they should hold on to it. It is always wise to be informed before investing any money into a company, and GoodWhale provides investors with the necessary information they require to make an informed decision. More…
Peers
The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.
– Nurix Therapeutics Inc ($NASDAQ:NRIX)
Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.
– Poxel SA ($LTS:0RA2)
Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.
Summary
Investing in Jazz Pharmaceuticals has recently become more attractive with the stock’s Relative Strength Rating increasing from 67 to 71. At the same time, media coverage has mostly been positive, making it a potentially attractive choice for investors. Jazz Pharmaceuticals is an international biopharmaceutical company dedicated to discovering, developing and commercializing innovative treatments for serious medical conditions. The company produces a variety of prescription products and specialty therapies for a range of diseases, such as cancer, sleep disorders, and neurological disorders.
The company is rapidly growing thanks to its commitment to research and development, a diversified and resilient business model, and extensive distribution network. Investors should research the company and its stock before diving into the market, as with any investment.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
